Clinical efficacy of the antitumor agent ONC201 in GBM
Ended Project Grant Awarded Last action
- Award ID
- R44CA192427
- Recipient
-
Oncoceutics, Inc. UEI ZKPGUP3MLBW9 Part of Chimerix, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $4,833,150
Award facts
- Assistance listing
- 93.395 Cancer Treatment Research
- Completion date
- Originally
- Place of performance
- Pennsylvania, USA
Award details come from USAspending.gov.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $999,250 | |
| Amendment | $0 | |
| Amendment | $999,600 | |
| Amendment | $999,600 | |
| Amendment | $0 | |
| Amendment | $224,700 | |
| Amendment | $552,548 | |
| Amendment | $847,452 | |
| Original award | $210,000 |
Show all 14
Quick answers
Who received award R44CA192427?
R44CA192427 was awarded to Oncoceutics, Inc. by National Cancer Institute (National Institutes of Health) on April 1, 2015.
How much is award R44CA192427 worth?
$4,833,150 has been obligated on R44CA192427.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award